Table 1.
Hypercapnia (PaCO2 ≥45 mmHg) | Hypercapnia (PaCO2 ≥50 mmHg) | |||
---|---|---|---|---|
Yes (n=58) | No (n=173) | Yes (n=20) | No (n=211) | |
Age, years | 66.4±9.1 | 67.5±8.9 | 64.3±8.6 | 67.5±9.0 |
Male, n (%) | 34 (59) | 111 (64) | 13 (65) | 132 (63) |
Body mass index, kg/m2 | 28.9±6.2 | 25.3±5.4 | 30.4±6.8 | 25.8±5.6 |
Smoking status, n (%) | ||||
Never | 4 (7) | 11 (6) | 2 (10) | 13 (6) |
Current | 17 (29) | 45 (26) | 5 (25) | 57 (27) |
Former | 37 (64) | 117 (68) | 13 (65) | 141 (67) |
GOLD stage 3, n (%) | 21 (36) | 114 (66) | 8 (40) | 127 (60) |
GOLD stage 4, n (%) | 37 (64) | 59 (34) | 12 (60) | 84 (40) |
Previous NIV, n (%) | ||||
None | 50 (86) | 168 (97) | 17 (85) | 201 (95) |
At home | 1 (2) | 0 | 1 (5) | 0 |
In hospital | 7 (12) | 5 (3) | 2 (10) | 10 (5) |
Disease history, n (%) | ||||
Heart failure | 8 (14) | 14 (8) | 2 (10) | 10 (5) |
Diabetes mellitus | 15 (26) | 26 (15) | 5 (25) | 36 (17) |
Hypertension | 34 (59) | 91 (53) | 14 (70) | 111 (53) |
Coronary artery disease | 9 (16) | 25 (14) | 2 (10) | 32 (15) |
Depression | 8 (14) | 22 (13) | 4 (20) | 26 (12) |
Obstructive sleep apnea | 6 (10) | 14 (8) | 3 (15) | 17 (8) |
Concomitant medication, n (%) | ||||
Roflumilast | 11 (19) | 18 (12) | 5 (25) | 24 (11) |
ß2-agonists | 55 (95) | 155 (90) | 19 (95) | 191 (91) |
Anticholinergics | 52 (90) | 152 (88) | 18 (90) | 186 (88) |
Methylxanthines | 7 (12) | 19 (11) | 2 (10) | 24 (11) |
Inhaled corticosteroids | 28 (48) | 89 (51) | 8 (40) | 109 (52) |
Systemic corticosteroids | 2 (3) | 8 (5) | 2 (10) | 8 (4) |
Inhaled + systemic corticosteroids | 0 | 3 (2) | 0 | 3 (1) |
Oxygen therapy, n (%) | ||||
Day | 0 | 2 (1) | 0 | 2 (1) |
Night | 0 | 1 (1) | 0 | 1 (<1) |
Day & night | 20 (34) | 26 (15) | 9 (45) | 37 (18) |
During exertion | 1 (2) | 0 | 0 | 1 (<1) |
None | 37 (64) | 143 (83) | 11 (55) | 169 (80) |
Abbreviations: GOLD, global initiative for obstructive lung disease; NIV, non-invasive ventilation; PaCO2, arterial carbon dioxide pressure.